The CD59 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited human cell population with targeted disruption of the CD59 gene. Generated as a polyclonal knockout pool, this product avoids clonal selection artifacts and provides a heterogeneous population of loss-of-function mutants. Cells uniformly lack CD59 protein expression, abolishing its complement-inhibitory function. The polyclonal format ensures consistent phenotypic robustness across experiments, ideal for complement sensitivity studies. Supplied as live cells, they are ready for immediate expansion and integration into diverse immuno-oncology workflows.
The parental NCI-H1975 cell line originates from pleural effusion of a female patient with non-small cell lung adenocarcinoma. It is a commonly used model in lung cancer research, characterized by EGFR and MET dysregulation and tumorigenic capacity in vivo. These cells exhibit epithelial morphology and retain clinically relevant signaling pathways, including cytokine-induced transcriptional programs. Their pulmonary origin makes them particularly suitable for investigating tumor immune evasion and complement system interactions within the lung microenvironment, providing a disease-relevant context for CD59 knockout studies.
CD59 is a GPI-anchored glycoprotein that inhibits the complement membrane attack complex (MAC) by binding C8 and C9, preventing their polymerization and pore formation. This protection is transcriptionally upregulated by TNF-?? and IL-1 via NF-??B and STAT3 signaling. Acting downstream of the terminal complement cascade (C5b, C6, C7, C8, C9), CD59 specifically interacts with C8 and C9 within the C5b-9 complex. By blocking MAC assembly, CD59 safeguards cells from complement-mediated lysis, a defense mechanism frequently co-opted by tumors.
Disruption of CD59 in NCI-H1975 cells completely abolishes complement-protective function, rendering them highly sensitive to complement-dependent cytotoxicity (CDC). This exactly models the loss of a critical tumor immune evasion mechanism in a lung adenocarcinoma setting. Given the cell line’s intrinsic oncogenic drivers and cytokine responsiveness, the CD59 knockout population provides a physiologically relevant system for probing complement resistance and the potential upregulation of other regulators such as CD46 and CD55. The polyclonal knockout format ensures that observed CDC susceptibility is a robust, population-level phenotype rather than a clonal artifact, making it suitable for quantitative and comparative studies.
These CD59-knockout cells are ideally suited for complement-dependent cytotoxicity (CDC) assays, flow cytometric monitoring of CD59 loss and C5b-9 surface deposition, and Western blot confirmation. Downstream viability and apoptosis assays reveal cell death pathways following complement attack. The model supports validation of CD59 as a therapeutic target and screening for complement-modulating agents. Additionally, it enables study of paroxysmal nocturnal hemoglobinuria-like phenotypes in solid tumors. Researchers in immunology and oncology will find this product indispensable for antibody-based immunotherapy development. For further details, contact Ascent Research.
